Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology.

摘要: BACKGROUND The unit equivalence between the two main Botulinum neurotoxin A (BoNTA) preparations, Dysport (Ipsen Ltd., Slough, Berkshire, UK) and BOTOX (Allergan Inc., Irvine, CA), is a matter of discussion. UK assay used to test more sensitive than U.S. for BOTOX, resulting in different efficacy per both formulations. Ratios ranging from 6:1 1:1 can be found literature, but recently published literature suggests that 1 equivalent approximately 2 4 units (ratio 2:1-4:1). OBJECTIVE Because number BoNTA treatments constantly increasing, these differences warrant systematic review evidence about METHODS based on detailed research all relevant databases (MEDLINE, PubMed, Cochrane Library, specialist textbooks). RESULTS present supports recent assumption dose ratios less 3:1 (e.g., 2.5:1 or even 2:1) are probably suitable. CONCLUSIONS current still insufficient, further investigation lower recommended.